OVERVIEW

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company with the potential to significantly disrupt the current cell therapy landscape. The Company is developing a portfolio of non-genetically modified, multi-antigen T cell therapies, which are able to recognize and kill heterogeneous tumors more effectively than conventional single-antigen CAR-T/TCR approaches.

Recent News

RECOGNITION

Marker Therapeutics, Inc. Congratulates Dr. James P. Allison for Receiving the 2018 Nobel Prize in Medicine or Physiology

Marker Therapeutics, Inc. Congratulates Dr. Padmanee Sharma for Receiving the William B. Coley Award for Distinguished Research in Tumor Immunology

At the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, Baylor College of Medicine Presented Data on Several Baylor Clinical Trials Employing Technology Exclusively Licensed to Marker

LATEST NEWS

null

Clinical Studies

Marker has multiple clinical studies ongoing and planned for its multi-antigen T cell therapies. Target indications include acute myelogenous leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and breast cancer.

null

Pipeline

Marker has a deep pipeline of clinical-stage programs that leverage the company’s unique multi-TAA cell therapy platform, addressing multiple hematologic malignancies and solid tumors. The company is also advancing its novel peptide vaccine in breast and ovarian cancer.

null

Technology

Marker’s unique cell therapy platform is the first to successfully target multiple tumor-associated antigens simultaneously, without the need for genetic modification of patients’ T cells. The result is a remarkably robust and durable anti-tumor immune response and a manufacturing process that is simpler and less costly than today’s TCR and CAR-T therapy.

null

Management Team

Marker is led by an executive management team specialized in cancer immunotherapy, bringing together extensive corporate, clinical, translational and medical experience. With its world-class scientific advisors, Marker is well positioned to advance its science-based approach to transforming the cell therapy landscape.